Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PTPRC | P08575 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21320375 | 0.92 | RECQL (0.39) | MEN1GAAKMT2APTPRCCA12 | |
| SCHEMBL5070504 | 0.84 | MAOA (0.41) | MEN1GAAKMT2APTPRCCA12 | |
| SCHEMBL6610608 | 0.83 | MEN1 (0.41) | MEN1GAAKMT2APTPRCCA12 | |
| SCHEMBL125503 | 0.81 | TDP1 (0.52) | MEN1GAAKMT2ACA12CA2 | |
| SCHEMBL7660758 | 0.81 | PTPRC (0.40) | MEN1GAAKMT2APTPRCCA12 | |
| SCHEMBL26760056 | 0.80 | PTPRC (0.37) | MEN1GAAKMT2APTPRCCA12 | |
| SCHEMBL16761943 | 0.80 | RECQL (0.41) | MEN1GAAKMT2APTPRCCA12 | |
| SCHEMBL23894059 | 0.80 | CA2 (0.41) | MEN1GAAKMT2APTPRCCA12 | |
| SCHEMBL783009 | 0.80 | CA2 (0.41) | MEN1GAAKMT2APTPRCCA12 | |
| SCHEMBL7660753 | 0.79 | PTPRC (0.39) | MEN1GAAKMT2APTPRCCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383914-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-21 | — | — | US | disclosed |
| US-12065446-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-20 | — | — | US | disclosed |
| US-20230174534-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2023-06-08 | — | — | US | disclosed |
| US-20230097422-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | US | disclosed |
| CN-113121562-B | Polycyclic compounds as inhibitors of bruton's tyrosine kinase | 詹森药业有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-11319329-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| EP-3889138-A1 | HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF | Hinova Pharmaceuticals Inc. (CN) | 2021-10-06 | — | — | EP | disclosed |
| CN-113121562-A | Polycyclic compounds as inhibitors of bruton's tyrosine kinase | 詹森药业有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-20210101910-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-08 | — | — | US | disclosed |
| US-10934310-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-02 | — | — | US | disclosed |
| US-20190276471-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-12 | — | — | US | disclosed |
| WO-2018103060-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | WO | disclosed |
| US-20170283430-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-05 | — | — | US | disclosed |
| EP-2894149-B1 | Cyanoguanidine prodrugs | LEO PHARMA AS (DK) | 2017-08-02 | — | — | EP | disclosed |
| EP-1339686-B1 | CYANOGUANIDINE PRODRUGS | LEO PHARMA AS (DK) | 2015-09-16 | — | — | EP | disclosed |
| EP-2894149-A1 | Cyanoguanidine prodrugs | LEO PHARMA A/S (DK) | 2015-07-15 | — | — | EP | disclosed |
| EP-1339686-A2 | CYANOGUANIDINE PRODRUGS | Leo Pharma A/S (DK) | 2003-09-03 | — | — | EP | disclosed |
| US-6525077-B2 | Antiproliferative agents | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-02-25 | — | — | US | disclosed |
| US-20020165201-A1 | Cyanoguanidine prodrugs | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-11-07 | — | — | US | disclosed |
| WO-2002042265-A2 | CYANOGUANIDINE PRODRUGS | LEO PHARMA A/S (DK) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934310-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | MEN1 2524/4885GAA 1131/4885KMT2A 2295/4885 |
| US-12065446-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | MEN1 2524/4885GAA 1131/4885KMT2A 2295/4885 |
| US-20230174534-A1 | COMPOUNDS USEFUL IN HIV THERAPY | CCR5, CD4, LSS | MEN1 4018/4885GAA 121/4885KMT2A 3306/4885 |
| US-20020165201-A1 | Cyanoguanidine prodrugs | CBR1, SIGMAR1, ROR1 | MEN1 4379/4885GAA 4017/4885KMT2A 2255/4885 |
| US-20170283430-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, LYN | MEN1 2524/4885GAA 1131/4885KMT2A 2295/4885 |
| US-20240383914-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | ABL1, BTK, MYLK2 | MEN1 2475/4885GAA 1257/4885KMT2A 2194/4885 |
| US-20230097422-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, LYN | MEN1 2524/4885GAA 1131/4885KMT2A 2295/4885 |
| US-20210101910-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | ABL1, BTK, MYLK2 | MEN1 2475/4885GAA 1257/4885KMT2A 2194/4885 |
| US-20190276471-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, LYN | MEN1 2524/4885GAA 1131/4885KMT2A 2295/4885 |
| US-11319329-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | ABL1, BTK, MYLK2 | MEN1 2475/4885GAA 1257/4885KMT2A 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.